perindopril has been researched along with Carcinoma, Hepatocellular in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdelghany, RH; El-Ahwany, E; Goda, R; Helal, NS; Mahmoud, AAA; Saber, S | 1 |
| Hamed, O; Kazem, A; Nasr, M; Selima, E | 1 |
| Fujimoto, M; Fukui, H; Ikenaka, Y; Kaji, K; Kawaratani, H; Kitade, M; Mitoro, A; Noguchi, R; Sawai, M; Toyohara, M; Tsujimoto, T; Uemura, M; Yamao, J; Yamazaki, M; Yoshida, M; Yoshiji, H | 1 |
| Aihara, Y; Fujimoto, M; Fukui, H; Ikenaka, Y; Kaji, K; Mitoro, A; Morioka, C; Noguchi, R; Sawai, M; Toyohara, M; Uemura, M; Yamao, J; Yamazaki, M; Yoshida, M; Yoshiji, H | 1 |
| Fukui, H; Ikenaka, Y; Imazu, H; Kitade, M; Kuriyama, S; Masaki, T; Mitoro, A; Namisaki, T; Noguchi, R; Tsujinoue, H; Yamazaki, M; Yanase, K; Yoshii, J; Yoshiji, H | 1 |
| Ikenaka, Y; Kuriyama, S; Noguchi, R; Yoshii, J; Yoshiji, H | 1 |
| Fukui, H; Ikenaka, Y; Kitade, M; Kuriyama, S; Masaki, T; Namisaki, T; Noguchi, R; Yamazaki, M; Yanase, K; Yoshii, J; Yoshiji, H | 1 |
| Fukui, H; Ikenaka, Y; Imazu, H; Noguchi, R; Tsujinoue, H; Yanase, K; Yoshii, J; Yoshiji, H | 1 |
2 trial(s) available for perindopril and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Carcinoma, Hepatocellular; Catheter Ablation; Drug Synergism; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Perindopril; Survival Rate; Vascular Endothelial Growth Factor A; Vitamin K 2 | 2009 |
Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial.
Topics: Aged; Amino Acids, Branched-Chain; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Insulin Resistance; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Perindopril; Treatment Outcome | 2011 |
6 other study(ies) available for perindopril and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cyclin D1; Diethylnitrosamine; Fosinopril; Liver Neoplasms, Experimental; Losartan; Male; Matrix Metalloproteinase 2; Mice; NF-kappa B; NF-KappaB Inhibitor alpha; Niacinamide; Perindopril; Phenylurea Compounds; Phosphorylation; Renin-Angiotensin System; Signal Transduction; Sorafenib; Time Factors; Transcription Factor RelA; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2018 |
Targeting different angiogenic pathways with combination of curcumin, leflunomide and perindopril inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Agents; Antirheumatic Agents; Carcinogens; Carcinoma, Hepatocellular; Curcumin; Diethylnitrosamine; Drug Therapy, Combination; Hypoxia-Inducible Factor 1, alpha Subunit; Isoxazoles; Leflunomide; Liver; Liver Neoplasms; Male; Mice; Neovascularization, Pathologic; Perindopril; Platelet Endothelial Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2014 |
Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Drug Combinations; Endothelium, Vascular; Humans; Interferon-beta; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Perindopril; Vascular Endothelial Growth Factor A | 2003 |
Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice.
Topics: Angiogenesis Inhibitors; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Chemoprevention; Drug Therapy, Combination; Interferon-beta; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Neovascularization, Pathologic; Perindopril | 2005 |
Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antifibrinolytic Agents; Carcinoma, Hepatocellular; Cell Division; Drug Therapy, Combination; Endothelium, Vascular; In Vitro Techniques; Liver; Liver Neoplasms; Male; Neovascularization, Pathologic; Perindopril; Precancerous Conditions; Rats; Rats, Inbred F344; Vitamin K 2 | 2005 |
Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Movement; Endothelial Growth Factors; Endothelium, Vascular; Liver Neoplasms; Lymphokines; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Neovascularization, Pathologic; Perindopril; Renin-Angiotensin System; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |